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Background: Bitter Melon (BM) is known for its hypoglycemic effect and is commonly used 
in populations. 
Objectives: This study examined the effects and safety of  bitter melon fruit in laboratory mice.
Materials and Methods: In this experimental study 70 male mice (25-30 gr) were randomly 
divided into 7 groups. The mice were injected intraperitoneally with single doses of  0, 100, 
500, 1000, 2000 and 4000 mg/kg and multiple doses 500 mg/kg daily for 7 days. The mice 
were then observed for 72 hours before sacrificing. Immediately kidneys were taken out for 
histological examinations. Tubular cell vacuolization and flattening as well as hyaline casts, 
debris and dilatation of  tubular lumen were the morphologic lesions which were assessed 
with scores from 0 to 4, while zero score addressed normal renal tissue. Serum samples were 
assayed for kidney function (creatinine; Cr and Blood Urea Nitrogen; BUN). Blood and bitter 
melon antioxidant activities were measured, too. Data were analyzed with Stata software 
(Stata Corp. 2011. Stata Statistical Software: Release 12. College Station, TX: Stata Corp LP) 
using ANOVA and Bonferroni tests.
Results: All single dose groups showed normal behavior after the dosing and no statistical 
changes were observed in blood parameters (p>0.05). Histological examinations revealed 
normal organ structures, however, the group treated for 7 days showed statistically a 
significant change in BUN (p=0.002) and a borderline significance in Cr (p=0.051). 
Conclusions: Administration of  up to 4000 mg/kg did not have any effect on the mice kidney 
function and histology, however chronic administration  were nephrotoxic. More studies with 
different dosage regimens are suggested.
Implication for health policy/practice/research/medical education:
Bitter melon is known for its hypoglycemic effect and is commonly used in populations. This study examined 
the effects and safety of  bitter melon fruit in laboratory mice. The results of  this study showed that 4000 mg/
kg of  M. charantia fruit extract (Bitter melon) as single dose has not any significant adverse effects on renal func-
tion and structure. Longer-term consumption for 7 days can cause some complications in kidney tissue and its 
function. We therefore can conclude that the consumption of  this drug for short time and low dose may have 
not toxicity effects on kidney tissues. However, long term treatment should be checked regularly and if  it has 
disrupting effects, the drug should be discontinued.
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1. Background 
Momordica charantia is a member of  Cucurbitace-
ae family known as bitter melon. It is grown in 
tropical and subtropical countries (1). This plant 
has traditionally been used as herbal medicine (2). 
The fruit contains charantin, momordium, carbo-
hydrates, mineral matters, ascorbic acid, alkaloids 
and glucosides. The ethanolic extract of  the fruit 
showed the presence of  proteins, alkaloids, tan-
nins, steroids, glycosides and carbohydrates and 
two classes of  saponins known as cleanane and 
oleanane (3,4). Bitter melon has positive effect on 
diabetes, blood pressure, immune system, pneu-
monia, cancer and infection (5-7). The extract of 
fruits has protective effect on diabetic kidney dis-
ease due to its antioxidant properties (8). Also it 
can stimulate insulin secretion and induce glucose 
uptake in liver in diabetic rats (9). In some exper-
imental studies, it has shown low toxicity follow-
ing oral intake (7-10). There are lots of  reports 
published on beneficial effects of  bitter melon, 
however side effects of  this plant have not been 
proven, yet (11,12). The aim of  this study was to 
examine the renal toxicity of  bitter melon with 
different concentrations of  this herb by evaluat-
ing serum creatinine, BUN and examining histo-
logical changes in kidneys of  mice.
2. Materials and Methods
2.1. Extraction procedure
Momordica charantia fruits were purchased from In-
dia and confirmed by expert botanist. Hydroalco-
holic extract was prepared by percolation method 
(13) with 95% ethanol, followed by steam evap-
oration (14). Five concentrations of  the extract 
were prepared. 
2.2. Phytochemical analysis
Total flavonoid content was estimated by alu-
minium chloride colorimetric method. Rutin was 
used as standard and different concentrations of 
25, 50, 100, 250 and 500 ppm in methanol 60% 
was prepared, then 1 ml of  each solution was 
transferred to a test tube and 1 ml solution of 
aluminum chloride 2% was added. Then 6 ml of 
potassium acetate 5% was added to the solution 
and after 40 minutes the absorbance was mea-
sured at 415 nm (15).
2.3. Measurement of  total phenol content
Total phenol content was determined by Fo-
lin-Ciocalteu reagent and the absorbance was 
measured at 760 nm. Total phenol content in 
terms of  mg/g of  dried extract was calculated 
(13). 
2.4. Antioxidant activity assays
β-Carotene/Linoleic Acid-Coupled Oxidation 
Reaction
A solution of  β-carotene was prepared by dissolv-
ing 2 mg in 10 mL of  chloroform. An amount of 
0.02 mL of  linoleic acid and 0.2 mL of  tween 40 
was afterward added, and the mixture was left at 
20°C for 15 min. After evaporation of  the chlo-
roform in a rotary evaporator at 40°C, 50 mL 
of  oxygen-saturated distilled water at 25°C was 
added and the mixture was vortexed strongly (1 
min) to form an emulsion (β-carotene/linole-
ic acid emulsion). The necessary wells of  a 96-
well microtiter plate were charged with different 
volumes of  sample and 100 μL of  emulsion per 
well. A control sample was also prepared the 
same. Absorbance measurements (470 nm) were 
made at t=0 min and after incubation at 50°C for 
120 min. All experiments were performed in trip-
licate. Antioxidant activity was expressed as the 
percent of  inhibition with respect to the control 
sample and calculated as follows:
{AA% = [1 − (S
A0
 − S
A1
)/ (C
A0
 − C
At
)] × 100}
where S
A0
 and C
A0
 are the absorbance values of 
the sample and the control determined at 0 min; 
the S
At
 and C
At
 are the absorbance values of  test 
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sample and control measured after 120 min. BHT 
was used as positive control (16).
2.5. Animals and treatments
In this experimental study 70 male db/db mice 
weighing 25-30 g were divided into seven groups 
with ten animals in each group as follows:
Group 1: control group (without drug) (sham 
group)
Group 2: received at 100 mg / kg extract as a 
single dose.
Group 3: received at 500 mg / kg extract as a 
single dose.
Group 4: received 1000 mg / kg extract as a sin-
gle dose.
Group5: received   2000 mg / kg extract as a sin-
gle dose.
Group 6:  received 4000 mg / kg extract as a sin-
gle dose.
Group 7: received   500 mg / kg/day for one 
week.
All the mice were maintained on a 12-h light/
dark cycle. All protocols for animal experiments 
were approved by the Animal Care Committee of 
Shahrekord University of  Medical Sciences An-
imal Care. All the experiments were done after 
one week in order for the mice to become accus-
tomed to the new environment and they could 
freely access water and food (17).
At the beginning of  the experiment blood sam-
ples were collected in test tubes without antico-
agulant (EDTA) for estimation of  biochemical 
parameters (18). After one week on the 8th day 
various doses of  extract were injected intraperi-
toneally to mice. The mice were observed for 72 
hours and then they were anesthesia and blood 
samples were collected in tubes for biochemical 
measurements (19). Then blood samples were 
centrifuged at 3500 rpm for 15 min to detect se-
rum creatinine and Blood Urea Nitrogen (BUN) 
(20). Serum Cr and BUN were measured by en-
zymatic method using standard kits, using Auto-
matic Analyzer 902 Hitachi (Germany) (21).
2.6. Ferric reducing ability
Ferric Reducing Ability of  Plasma (FRAP) re-
agent was mixed with 90 μl of  distilled water and 
30 μl of  test sample solutions. The reaction mix-
ture was then incubated at 37°C for 10 minutes 
and absorbance was recorded at 593 nm, using 
a spectrophotometer (uv3100 Shimadzu, Japan). 
The concentrations of  FeSO4 were in turn plot-
ted against concentrations of  the standard anti-
oxidants (22).
2.7. Histological study
After animals were euthanized by ether, livers and 
kidneys were collected and put into 10% buffered 
formalin for 48 h. Then, organs were embedded 
within paraffin. Solid sections of  5 μm thickness 
were made using a microtome. The sections were 
stained with hematoxylin and eosin and then ob-
served by light microscopy for histopathological 
examinations (20). In this study morphology of 
tubular cells of  kidney were observed. Renal tu-
bular damages of  tissue samples were assessed 
using damage scores from 0 to 4. The ratings 
were as follows:
Score 0 = normal tubular cells, score 1= 0-19 % 
tubular cell injury,  score 2= 20-49 %  tubular cell 
injury, score 3= 50-69% tubular cell injury and 
score 4 was considered 70-100 tubular cell injury 
(21-23). Tissue damages including cell loss and 
degeneration, hyaline casts, intra-tubular debris, 
tubular cell vacuolization, flattening and dilata-
tion were scored (22,23). 
2.8. Statistical analysis
Data were analyzed with Stata software (Stata 
Corp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: Stata Corp LP) using ANO-
VA and Bonferroni tests. P<0.01 was considered 
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significant for all data.
3. Results
Antioxidant capacity of  bitter melon (percent in-
hibition of  peroxidation in linoleic acid produc-
tion) was calculated to be 68%. The amount of 
the extract flavonoid was 54 μg/g, flavonol was 
45 μg/g and the amount of  phenolic content was 
413 μg/g. 
3.1. Antioxidant capacity of  the blood
Antioxidant capacity of  blood before interven-
tion was 568 µmol/lit and at the end of  the ex-
periment in different groups was as follows:
Group 1: (control group) 564 µmol/lit, Group 
2: 1108 µmol/lit, Group 3: 741 µmol/lit, Group 
4: 553 µmol/lit, Group5: 703 µmol/lit, Group 6: 
624 µmol/lit and Group 7: 436 µmol/lit.
3.2. Plasma creatinine and BUN levels 
According to Table 1, between groups there are 
no significant differences in terms of  creatinine 
levels (p=0.0517). Comparison of  BUN between 
groups showed that there were significant differ-
ences between groups 7 and 1 (p=0.026), 7 and 4 
(p=0.025) and 7 and 6 (p=0.001).
Table 1. Comparison (mean ±SD) of  serum creatinine and 
blood urea nitrogen levels in the study groups
Groups BUN (mg/dl) Cr (mg/dl)
1(Control) 31.6±2.6 0.34±0.07
2(100 mg/kg) 32.2±2.5 0.39±0.11
500 mg/kg))3 32.7±4.3 0.45±0.15
4(1000 mg/kg) 31.8±3.6 0.42±0.09
5(2000 mg/kg) 32.6±2.8 0.38±0.03
6(4000 mg/kg) 28.6±2.9 0.41±0.07
7(500 mg/kg/day) 37±3.6* 0.48±0.1
P Value 0.0002* 0.0517
Data are shown as the Mean ±SEM, n=7 (p<0.05).
3.3. Effects of  different doses of  Momordica charantia 
on renal histology 
There were no significant differences for mor-
phologic variables of  cell loss and cell debris 
between groups (p=0.064). However, there were 
significant differences between the scores of 
group 7 and other groups in other variables as 
follows:
Variable Score Between group 7 and groups 4, 5 
and 6 was significant (p=0.01), vacuoles between 
group 7 and groups 4, 5 (p=0.004), and cell dam-
age between group 7 and group 4 (p=0.047). 
There was a borderline significant difference be-
tween group 7 and groups 1 and 6 for hyaline 
(p=0.054) vacuoles between groups 7 and 4 & 
5 (p=0.004), and cell damage between groups 7 
and 4 (p=0.047) were significant respectively.
4. Discussion 
In this study, 70 mice in 7 groups were treated 
with different doses of  Momordica charantia ex-
tract. The lowest dose was 100 mg/kg and the 
maximum dose was 4000 mg/kg. Also, a group 
was treated with 500 mg/kg/day for one week. In 
this study the kidney function test was assessed 
measuring BUN and Cr. Also morphologic le-
sions of  renal histology were examined. BUN and 
Cr levels of  the group which was treated for one 
week was not significantly different compared to 
the control and other groups.
The results in our study were in accord with the 
results of  another study which was carried out 
on 30 male Wistar rats to evaluate the effect of 
polypeptide isolated from seeds of  Momordica 
charantia in which the animals were divided into 
three groups and treated with single dose of  the 
extract. The animal groups were treated with 
doses of  0, 500 or 1000 mg/kg and were moni-
tored for 72 hours, then BUN and Cr and renal 
morphologic lesions were assessed. The results 
showed that there was no significant difference 
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Table 2. Comparison of  changes in the scores of  histology variable in the cells and tissues of  the studied groups.
Groups Score
Tubular 
dilatation
Cell 
damage Vacuoles Cell debris
Hyaline 
casts
Cell loss
(Control)1 2.7±1 0 1.3±1 1.4±1 0.1±0.3 0 0
2(100 mg/kg) 1.8±1 0 1.1±1 0.7±0.9 0 0 0
500 mg/kg))3 2.4±2 0.1±0.3 1.1±1 1.1±1 0.2±0.4 0.1±0.3 0
4(1000 mg/kg) 1±1 0.1±0.3 0.6±0.9 0.2±0.6 0.1±0.3 0.1±0.3 0
5(2000 mg/kg) 1.7±2 0.2±0.6 0.8±1 0.5±1 0.3±0.6 0.1±0.3 0.1±0.3
6(4000 mg/kg) 2±3 0.4±0.8 0.8±1 0.8±1 0.1±0.3 0 0
7(500 mg/kg/d) 6.3±5 0.2±0.4 2.5±1* 3±3* 0 0.6±0.9 0
F Ratio(ANOVA) 3.35 0.92 2.24 3.56 0.86 2.48 1
P- value 0.0064* 0.48 0.05  0.006* 0.064 0.0326* 0.43
Data are shown as the Mean ±SEM, n=7 (*p<0.05 was significant).
for different parameters between groups which 
received the extract and control group (12). 
The results of  the present study showed that kid-
ney tissue treated with 4000 mg/kg as single dose 
of  Momordica charantia did not cause any damage 
in the kidneys tissues; however a week-long drug 
treatment led to some pathological changes in the 
kidneys of  mice. In the study of  Nazrul-Hakim 
et al, histological examination showed that till 
1000 mg/kg dose of  bitter melon for 72 hours 
would not cause any change in renal structure of 
mice (26). Furthermore, tubular cell   destruction, 
necrosis and hemorrhage in kidneys of  mice af-
ter treatment with Bitter melon fruit juice was 
observed for two weeks (26). The results of  this 
study are endorsing the results of  our research.
5.Conclusions
The results of  this study show that 4000 mg/kg 
of  Momordica charantia fruit extract as single dose 
has not any significant adverse effects on renal 
function and structure. Longer-term consump-
tion for 7 days can cause some complications in 
kidney tissue and its function. We therefore can 
conclude that the consumption of  this drug for 
short time and low dose may have not toxicity 
effects on kidney tissues. However, long term 
treatment should be checked regularly and if  it 
has disrupting effects, the drug should be discon-
tinued.
Authors’ contributions
SM, MRK and RK conducted the research. AA 
analyzed the data. HN and SH prepared the pri-
mary draft. MRK edited the manuscript.
Conflict of  interests
The author declared no competing interests.
Funding/Support
This paper has been derived from MD thesis. 
This study was granted by Shahrekord University 
of  Medical Sciences (Grant# 1182).
References 
1. Raja GK, Mahmood T, Gulfraz M, Khanum A. Iso-
lation and characterization of  antimicrobial activity 
conferring component(s) from seeds of  bitter gourd 
(Momordica charantia). J Med Plants Res 2012; 13(4): 
566–573.
2. Bano F, Akthar N, Naz H. Effect of  the aqueous ex-
tract of  Momordica charantia on body weight of  rats. 
J Basic Appl Sci 2011; 13(1):1–5.
40
Mardani H et al.
Journal of  Nephropathology, Vol 3 No 1, January 2014        www.nephropathol.com
3. Patel R, Mahobia N, Upwar N, Waseem N, Talaviya 
H, Patel Z. Analgesic and antipyretic activities of  Mo-
mordica charantia linn fruits. J Adv Pharm Technol 
Res 2010; 1(4):415-8.
4. Popovich DG, Li L, Zhang W. Bitter melon (Momor-
dica charantia) triterpenoid extract reduces preadipo-
cyte viability, lipid accumulation and adiponectin ex-
pression in 3T3-L1 cells. Food Chem Toxicol 2010; 
48(6):1619-1626.
5. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momor-
dica charantia): a review of  efficacy and safety. Amer-
ican. Journal of  Health and Systemic Pharmacology 
2003;60(4):356-9.
6. Lee-Huang S, Huang PL, Sun Y, Chen HC, Kung HF, 
Huang PL, et al. Inhibition of  MDA-MB-231 human 
breast tumor xenogrfats and HER2 expression by an-
ti-tumor agents GAP31 and Map 30. Anticancer Res 
2000; 20(2A): 653-659.
7. Ilikci Sagkan R. An in vitro study on the risk of 
non-allergic type-I like hypersensitivity to Momordi-
ca charantia. BMC Complement Altern Med 2013; 
13(1):284-289.
8. Teoh SL, Abd Latiff  A, Das S. Histological changes 
in the kidneys of  experimental diabetic rats fed with 
Momordica charantia (bitter gourd) extract. Rom J 
Morphol Embryol 2010; 51(1):91-5.
9. Garau C, Cummings E, Phoenix DA, Singh J. Bene-
ficial effect and mechanism of  action of  Momordica 
charantia in the treatment of  diabetes mellitus: a mini 
review. Int J Diabetes & Metabolism 2003;11:46-55.
10. Marles R, Farnsworth N. Antidiabetic plants and 
their active constituents; an update. Phytomedicine 
1995;2(2):137-89. 
11. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momor-
dica charantia): a review of  efficacy and safety. Am J 
Health Syst Pharm 2003; 60(4):356-9.
12. Nazrul-Hakim M, Yaacob A, Adam Y, Zuraini A. Pre-
limi nary toxicological evaluations of   polypeptide-K 
Isolated from Momordi charantia in laboratory rats. 
World Academy of  Science, Engineering and Technol-
ogy 2011; 51: 590-593.
13. Nasri H. World kidney day 2013: acute kidney inju-
ry; a public health aware. Iran J Public Health 2013; 
42(3):338-40.
14. Asadi SY, Parsaei P, Karimi M, Ezzati S, Zamiri A, 
Mohammadizadeh F, et al. Effect of  green tea (Ca-
mellia sinensis) extract on healing process of  surgical 
wounds in rat. Int J Surg 2013;11(4):332-7.
15. Ansari R, Shahinfard N, Namjou A, Rafieian M, 
Shirzad H, Rafieian-kopaei M. Ameliorative prop-
erty of  Teucrium polium on second degree burn. J 
HerbMed Plarmacol 2013;2(1):9-11.
16. Shirzad H, Taji F, Rafieian-Kopaei M. Correlation 
between antioxidant activity of  garlic extracts and 
WEHI-164 fibrosarcoma tumor growth in BALB/c 
mice. J Med Food 2011;14(9):969-74. 
17. Nittby H, Ericsson P, Förnvik K, Strömblad S, Jansson 
L, Xue Z, et al. Zebularine Induces Long-Term Sur-
vival of  Pancreatic Islet Allotransplants in Streptozo-
tocin Treated Diabetic Rats. PLoS One 2013; 8(8):1-8.
18. Sabitha V, Ramachandran S, Naveen KR, Panneer-
selvam K. Anti-diabetic and anti hyperlipidemic po-
tential of  Abelmoschus esculentus (L.) Moench. In 
streptozotocin-induced diabetic rats. J Pharm Bioal-
lied Sci 2011; 3(3): 397-402.
19. Dixit VP, Khanna P, Bhargava SK. Effects of  Momor-
dica charantia L. fruit extract on the testicular function 
of  dog. Planta Med 1978; 34: 280-6.
20. Liu Z, Wan L, Yue Y, Xiao Z, Zhang Y, Wang Y, et 
al. Hypoglycemic Activity and Antioxidative Stress of 
Extracts and Corymbiferin from Swertia bimaculata In 
Vitro and In Vivo. Evid Based Complement Alternat 
Med 2013; 2013:125416. 
21. Shahraki M, Mirimoghadam A, Palan M. Study of  tox-
icity of  Teucrium polium extract on liplid profile in 
male rats. Tabibe Shargh 2006;8(3):227-232.
22. Kaushik A, Jijta C, Kaushik J, Zeray R, Ambesajir A, 
Beyene L. FRAP (Ferric reducing ability of  plasma) 
assay and effect of  diplazium esculentum (Retz) Sw. 
Indian Journal of  Natural Products and Resources 
2012; 3(2): 228-231.
23. Nasri H, Nematbakhsh M, Rafieian-Kopaei M. Ethan-
olic extract of  garlic for attenuation of  gentamicin-in-
duced nephrotoxicity in Wistar rats. Iran J Kidney Dis 
2013; 7(5):376-82.
24. Pooladvand V, Taghavi M, Mahmoodi M, Tvakolian 
V. histological ghanges due to different doseage of  Ci-
trullus colocynthis in normal and diabetic  male rats. 
Mazandaran Medical Science 2011; 21(82): 63-71.
25. Kumar A, Fausto R. Cotran Pathologic Basis of  Dis-
ease. 2007. 7th ed. Unit 2, chapter 20: 955-1022.
26. Faraj S. Haemorrhagic colitis induced by Citrullus co-
locynthis. Ann Trop Med Parasit 1995; 89(6): 695-696.
